Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

Recruiting now

Conditions studied: Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers

In brief

This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

Key facts

Study ID

NCT07701161

Run by

Neurogen Biomarking LLC

People needed

1000

Starts

2025-01-13

Expected to finish

2026-08-01

Last updated by the study team

2026-07-14

Who can join

Age: 40 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed

You may not qualify if…

• Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use

Where it is running

• Insigth Hospital and Medical Center Chicago — Chicago, Illinois, United States (enrolling)
• Insight Hospital and Medical Center Dearborn — Dearborn, Michigan, United States
• Insight Institute of Neurology and Neurosurgery — Flint, Michigan, United States
• Memorial Healthcare Hospital — Owosso, Michigan, United States
• Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.